

Outlook Therapeutics, Inc. Logo

## Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference

January 4, 2022

ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the virtual [H.C. Wainwright BioConnect Conference](#) taking place January 10-13, 2022.

A [video webcast](#) of the fireside chat will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the conference and will be accessible on the [Events](#) page of the [Investors](#) section of the Outlook Therapeutics website, [outlooktherapeutics.com](#).

### About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHS 351(a) regulatory pathway. For more information, please visit [www.outlooktherapeutics.com](#).

### CONTACTS:

#### Media Inquiries:

Harriet Ullman  
Vice President  
LaVoie Health Science  
T: 617-669-3082  
[hullman@lavoiehealthscience.com](mailto:hullman@lavoiehealthscience.com)

#### Investor Inquiries:

Jenene Thomas  
Chief Executive Officer  
JTC Team, LLC  
T: 833.475.8247  
[OTLK@jtcir.com](mailto:OTLK@jtcir.com)



Source: Outlook Therapeutics, Inc.